Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1

2(40.0%)

Phase 4

1(20.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

5Total

Early Phase 1(2)

Phase 4(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02153684Completed

Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform

Role: lead

NCT04069052Early Phase 1Completed

The Effect of Inhaled Nitric Oxide on Deadspace in COPD

Role: lead

NCT04920695Not ApplicableCompleted

Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE)

Role: lead

NCT03018756Phase 3Completed

Nebulized Fentanyl in Patients With Mild to Moderate Interstitial Lung Disease and Chronic Dyspnea

Role: lead

NCT03405090Phase 4Completed

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators

Role: lead

NCT05052229Early Phase 1Recruiting

Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).

Role: lead

NCT03786367Completed

Dyspnea in Chronic Thromboembolic Pulmonary Hypertension

Role: lead

All 7 trials loaded